[Analysis of drug resistance of Acinetobacter baumannii and its related factors in ICU]
- PMID: 24225215
- DOI: 10.3760/cma.j.issn.2095-4352.2013.11.012
[Analysis of drug resistance of Acinetobacter baumannii and its related factors in ICU]
Abstract
Objective: To investigate drug resistance of Acinetobacter baumannii and its related factors in intensive care unit (ICU), and to provide clinical basis for prevention and treatment.
Methods: A retrospective analysis was conducted. Clinical data was collected from 1 050 patients in ICU of Foshan Hospital of Traditional Chinese Medicine from January 2011 to June 2013. The risk factors of nosocomial infection were analyzed with univariate analysis. The independent risk factor was sieved from the risk factors with P<0.05 with unconditional logistic regression analysis to analyze the related factors and drug resistance of Acinetobacter baumannii in ICU.
Results: One hundred and thirteen patients suffering from nosocomial infection of Acinetobacter baumannii were found, and its incidence rate was 10.76%. There were 96 cases of infection of multi-drug resistant, extensive-drug resistant and pan-drug resistant Acinetobacter baumannii, accounting for 84.96%. Acinetobacter baumannii detection rate was 79.65% in sputum, 10.62% in urine, 4.42% in wound secretion, 3.54% in blood, and 1.77% in other drainage discharges, respectively. Univariate analysis showed that mechanical ventilation, ICU stay time≥7 days, coma [Glasgow coma score (GCS)<8], usage of broad-spectrum antibiotics were risk factors of nosocomial infection of Acinetobacter baumannii. Multivariate logistic analysis showed that the independent risk factors of nosocomial infection caused by Acinetobacter baumannii in ICU were mechanical ventilation [odds ratio (OR)= 2.957, 95%confidence interval (95%CI) 1.106-6.253, P=0.023], ICU stay time≥7 days (OR=2.991, 95%CI 1.135-6.544, P=0.022), coma (GCS<8,OR=2.894, 95%CI 1.803-7.462, P=0.010), and usage of broad-spectrum antibiotics (OR=3.054, 95%CI 1.009-6.550, P=0.004). Rate of resistance to polymyxin B was the lowest (6.19%), and it was followed by tobramycin and tigecycline, 11.50% and 28.32%, respectively.
Conclusions: Acinetobacter baumannii in ICU was conditional pathogenic bacteria with high infection rate, and the lower respiratory tract was the main site of infestation. The related factors include mechanical ventilation, ICU stay time, coma, usage of broad-spectrum antibiotics. Its antimicrobial resistance rate was high. Comprehensive measures, including environmental isolation, strict bed unit disinfection, enforcement of hand disinfection, strengthening the effort to shorten the duration of mechanical ventilation, reduction of ICU length of stay, enhancement of drainage of mucus, excretions, and other body fluids, and rational use of antibiotics should be encouraged in order to reduce Acinetobacter baumannii in ICU.
Similar articles
-
Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections.Int J Infect Dis. 2008 Jan;12(1):16-21. doi: 10.1016/j.ijid.2007.03.005. Epub 2007 May 21. Int J Infect Dis. 2008. PMID: 17513154
-
[Antibiotic resistance of Acinetobacter baumannii strains isolated from clinical specimens in the "Marius Nasta" Pneumology Institute, Bucharest].Pneumologia. 2014 Apr-Jun;63(2):109-11. Pneumologia. 2014. PMID: 25241558 Romanian.
-
Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.Southeast Asian J Trop Med Public Health. 2011 May;42(3):693-703. Southeast Asian J Trop Med Public Health. 2011. PMID: 21706949
-
Treatment of Acinetobacter infections.Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350. Expert Opin Pharmacother. 2010. PMID: 20210684 Review.
-
[Multidrug resistant Acinetobacter baumanii:clinical update and new highlights].Rev Esp Quimioter. 2010 Mar;23(1):12-9. Rev Esp Quimioter. 2010. PMID: 20232019 Review. Spanish.
Cited by
-
Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of tigecycline for post‑neurosurgical intracranial infections due to MDR/XDR Acinetobacter baumannii: A retrospective cohort study.Exp Ther Med. 2024 Dec 13;29(2):31. doi: 10.3892/etm.2024.12781. eCollection 2025 Feb. Exp Ther Med. 2024. PMID: 40486899 Free PMC article.
-
Infection Control Programs and Antibiotic Control Programs to Limit Transmission of Multi-Drug Resistant Acinetobacter baumannii Infections: Evolution of Old Problems and New Challenges for Institutes.Int J Environ Res Public Health. 2015 Jul 30;12(8):8871-82. doi: 10.3390/ijerph120808871. Int J Environ Res Public Health. 2015. PMID: 26264006 Free PMC article. Review.
-
Monitoring Multidrug-Resistant Acinetobacter baumannii Infections in the Neurosurgery ICU Using a Real-Time Surveillance System.Pol J Microbiol. 2022 Mar 30;71(1):107-114. doi: 10.33073/pjm-2022-013. Pol J Microbiol. 2022. PMID: 35635170 Free PMC article.
-
Bispectral index in predicting the prognosis of patients with coma in intensive care unit.World J Emerg Med. 2014;5(1):53-6. doi: 10.5847/wjem.j.issn.1920-8642.2014.01.009. World J Emerg Med. 2014. PMID: 25215148 Free PMC article.
-
Interaction of an Acinetobacter baumannii's Membrane Protein with Human Fibronectin to Evade Immune Response.Chemistry. 2025 Aug 13;31(45):e00874. doi: 10.1002/chem.202500874. Epub 2025 Jul 25. Chemistry. 2025. PMID: 40708401 Free PMC article.